Study on Hydroxyurea Response in Hemoglobinopathies Patients Using Genetic Markers and Liquid Erythroid Cultures

Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies. Hydroxyurea (HU) is the only inducer approved for the treatment of these diseases able to stimulate HbF production but patients’ response is highly variable indicating the utility of the identifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sclafani, Serena, Pecoraro, Alice, Agrigento, Veronica, Troia, Antonio, Di Maggio, Rosario, Sacco, Massimiliano, Maggio, Aurelio, D’Alcamo, Elena, Di Marzo, Rosalba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178820/
https://www.ncbi.nlm.nih.gov/pubmed/28053695
http://dx.doi.org/10.4081/hr.2016.6678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178820/
https://www.ncbi.nlm.nih.gov/pubmed/28053695
http://dx.doi.org/10.4081/hr.2016.6678

Ejemplares similares